MYOCARDITIS-MYOSITIS-MYASTHENIA GRAVIS OVERLAP SYNDROME

This adverse event was reported 228 times

These drugs are most commonly taken by patients reporting MYOCARDITIS-MYOSITIS-MYASTHENIA GRAVIS OVERLAP SYNDROME:

# Drug Count
0 NIVOLUMAB 59
1 CARBOPLATIN 38
2 IPILIMUMAB 32
3 PACLITAXEL 24
4 DURVALUMAB 21
5 PEMETREXED DISODIUM 19
6 PEMETREXED 17
7 CISPLATIN 15
8 METHYLPREDNISOLONE 12
9 GEMCITABINE HYDROCHLORIDE 9
See all common drugs associated with MYOCARDITIS-MYOSITIS-MYASTHENIA GRAVIS OVERLAP SYNDROME

MYOCARDITIS-MYOSITIS-MYASTHENIA GRAVIS OVERLAP SYNDROME is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 NIVOLUMAB AND RELATLIMAB-RMBW 2 0.0039
1 CEMIPLIMAB-RWLC 6 0.0029
2 TREMELIMUMAB 8 0.0018
3 PYRIDOSTIGMINE BROMIDE ORAL 6 0.0017
4 DURVALUMAB 21 0.0010
5 ETHIODIZED OIL 1 0.0008
6 IPILIMUMAB 32 0.0007
7 NIVOLUMAB 59 0.0006
8 ENFORTUMAB VEDOTIN 4 0.0005
9 PEMETREXED DISODIUM 19 0.0005
See all drugs enriched for association with MYOCARDITIS-MYOSITIS-MYASTHENIA GRAVIS OVERLAP SYNDROME